Risks and Opportunities of AI in Clinical Drug Development
Due to COVID-19 the event has been postponed until 2021. Details forthcoming.
We have left the schedule up here for reference. These dates and times no longer apply.
Click on each event title for a full description and abstracts.
Opening Plenary Session (Chair D. Madigan)
A Perspective on the Promise and Pitfalls of Artificial Intelligence in Clinical Drug Development — Kannan Natarajan, Pfizer Inc.
Find out more »Keynote Address (Chair D. Madigan)
Machine Learning: Changing the future of healthcare - from next generation clinical trials to individualized treatment effects — Mihaela van der Schaar, University of Cambridge
Discussant — Patrick Ryan, Janssen Research and Development
Find out more »Plenary Session I (Chair, D. Alemayehu, Pfizer Inc)
ML and AI in Clinical Development and Statistical Innovation — Wang Li, AbbVie.
Opportunities for AI in Healthcare — Lawrence Carin, Duke University
Find out more »Plenary Session II (Chair, John Doyle, Pfizer)
Data-Powered Patient-Centered Care — Noémie Elhadad, Columbia University.
Artificial Intelligence in Pharmaceutical R&D at AstraZeneca — Faisal Khan, AstraZeneca
Find out more »Fireside Chat (Moderator K. Natarajan)
Amy Abernethy, U.S. Food and Drug Administration.
Find out more »Plenary Session III (Chair, Javier Cabrera, Rutgers)
Bias from Treatment Contamination in Clinical Decision Rules — Amol Navathe, University of Pennsylvania.
Finding Natural Experiments in Observational Data — Adler Perotte, Columbia University.
Discussant — Jesse Berlin, Johnson & Johnson.
Find out more »Panel Discussion: Ethical and Regulatory Issues with AI in Clinical Drug Development
Moderator: Jeannette M. Wing, Columbia University. Panelists: Graeme Archer, GlaxoSmithKline. Igor Jurisica, Krembil Research Institute & Univ of Toronto. Simon Tavaré, Columbia University.
Find out more »